Launch comes immediately after FDA approval of Dr. Reddy's and Mylan ANDAs while Indivior appeals district court ruling of non-infringement; Mylan settlement may delay its entry.

The potential blockbuster category for abuse-deterrent opioids has fizzled. A few stalwarts are pushing on, but the return on investment for many drug manufacturers has been disappointing. Scrip tracked how opioids approved in the last eight years have performed.

KemPharm is looking to sign a generic drug partner to launch its new brand opioid Apadaz, which says a lot about how the commercial promise of abuse-deterrent opioids has so far failed to materialize.